Embeda Articles
Watson temporarily restrained from marketing generic Lovenox; challenges Pfizer’s Embeda patent
10 October 2011
King updates on pain pipeline at APS
11 May 2009
Stock Commentary - New York week to April 20, 2009
23 April 2009
Stock Commentary - New York week to April 13, 2009
16 April 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
King's Embeda "effective for up to 12 months"
9 February 2009
FDA review of King's Embeda likely to extend into "early 2009"
12 January 2009
Alpharma relents, accepting King Pharma
1 December 2008
Stock Commentary - New York week to Nov 17, 2008
24 November 2008
UPDATE: King "committed" to $1.4B bid for Alpharma, seeks to strengthen painkiller franchise
1 September 2008
Showing 1-11 of 11 articles
- 1
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
